AR031844A1 - ENZYMATIC RESOLUTION OF SELECTIVE MODULATORS OF STROGEN RECEIVERS - Google Patents
ENZYMATIC RESOLUTION OF SELECTIVE MODULATORS OF STROGEN RECEIVERSInfo
- Publication number
- AR031844A1 AR031844A1 ARP010102123A ARP010102123A AR031844A1 AR 031844 A1 AR031844 A1 AR 031844A1 AR P010102123 A ARP010102123 A AR P010102123A AR P010102123 A ARP010102123 A AR P010102123A AR 031844 A1 AR031844 A1 AR 031844A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently selected
- ring
- substituents independently
- Prior art date
Links
- 230000002255 enzymatic effect Effects 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004882 Lipase Human genes 0.000 abstract 1
- 108090001060 Lipase Proteins 0.000 abstract 1
- 239000004367 Lipase Substances 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 239000012062 aqueous buffer Substances 0.000 abstract 1
- -1 bicyclic amine Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000006196 deacetylation Effects 0.000 abstract 1
- 238000003381 deacetylation reaction Methods 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 235000019421 lipase Nutrition 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01013—Sterol esterase (3.1.1.13)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
Un procedimiento para la preparacion de un compuesto de formula 1 en la que A se selecciona de CH2 y NR; B, D y E se seleccionan independientemente de CH y N; Y es (a) fenilo, opcionalmente sustituido con 1-3 sustituyentes seleccionados independientemente de R4; (b) naftilo, opcionalmente sustituido con 1-3 sustituyentes seleccionados independientemente de R4; (c) cicloalquilo (C3-8), opcionalmente sustituido con 1-2 sustituyentes seleccionados independientemente de R4; (d) cicloalquinilo (C3-8), opcionalmente sustituido con 1-2 sustituyentes seleccionados independientemente de R4; (e) un heterociclo de cinco miembros que contiene hasta dos heteroátomos seleccionados del grupo constituido por -O-, -NR2- y -S(O)n-, opcionalmente sustituido con 1-3 sustituyentes seleccionados independientemente de R4, (f) un heterociclo de seis miembros que contiene hasta dos heteroátomos seleccionados del grupo constituido por -O-, -NR2- y -S(O)n-, opcionalmente sustituido con 1-3 sustituyentes seleccionados independientemente de R4; o (g) un sistema de anillo bicíclico constituido por un anillo heterocíclico de cinco a seis miembros condensado con un anillo fenilo, conteniendo el citado anillo heterocíclico hasta dos heteroátomos seleccionados del grupo constituido por -O-, -NR2-, NR2- y -S(O)n-, opcionalmente sustituido con 1-3 sustituyentes seleccionados independientemente de R4; Z1 es (a) -(CH2)pW(CH2)q-; (b) -O(CH2)pCR5R6-; (c)-O(CH2)pW(CH2)q; (d) -OCHR2CHR3-; o (e)-SCHR2CHR3-; G es (a) -NR7R8; (b) formula (2) en la que n es 0, 1 o 2; m es 1, 2 o 3; Z2 es -NH-, -O-, -S-, o -CH2-; opcionalmente condensado sobre átomos de carbono adyacentes con uno o dos anillos fenilo y sustituido opcional e independientemente sobre carbono con uno a tres sustituyentes y opcional e independientemente, sobre nitrogeno con un sustituyente químicamente adecuado seleccionado de R4; o (c) una amina bicíclica que contiene de cinco a doce átomos de carbono, que forma un puente o está condensada, y opcionalmente sustituida con 1-3 sustituyentes seleccionados independientemente de R4; Z1 y G combinados pueden ser formula (3); W es (a) -CH2-; (b) -CH=CH-; (c) -O-; (d) -O-; (d) -NR2-; (e) -S(O)n-; (f) >C=O, (g) -CR2(OH)-; (h) -CONR2-; (i) -NR2CO-; (j) formula (4) o (k) ûCsC-; R es hidrogeno o alquilo (C1-6); R2 y R3 son independientemente (a) hidrogeno; o (b) alquilo (C1-4); R4 es (a) hidrogeno; (b) halogeno; (c) alquilo (C1-6); (d) alcoxi (C1-4); (e) aciloxi (C1-4); (f) alquiltio (C1-4); (g) alquilsulfinilo (C1-4); (h) alquilsulfonilo (C1-4); (i) hidroxialquilo (C1-4); (j) arilalquilo (C1-4); (k) -CO2H; (l) -CN; (m) -CONHOR; (n) -SO2NHR; (o) -NH2; (p) alquil (C1-4) amino; (q) dialquil (C1-4) amino; (r) -NHSO2R; (s) -NO2; (t) -arilo; o (u) -OH: R5 y R6 son independientemente alquilo (C1-8) o forman conjuntamente un anillo carbocíclico C3-10; R7 y R8 son independientemente (a) fenilo; (b) un anillo carbocíclico (C3-10) saturado o insaturado (c) un anillo heterocíclico (C3-10) que contiene hasta dos heteroátomos, seleccionados de O-, -N- y -S-; (d) H, (e) alquilo C1-6; o (f) forman un anillo de 3 a 8 miembros que contienen nitrogeno con R5 o R6; R7 y R8 en forma lineal o de anillo pueden estar opcionalmente sustituidos con hasta tres sustituyentes seleccionados independientemente de alquilo (C1-6), halogeno, alcoxi, hidroxi, y carboxi; el anillo formado por R7 y R8 puede estar opcionalmente condensado con un anillo fenilo; ( )e y ( )n son (CH2)e y (CH2)n respectivamente; e es 0, 1 o 2;; m es 1, 2 o 3; n es 0, 1 o 2; p es 0, 1, 2, o 3; q es 0, 1 , 2 o 3; y los isomeros opticos y geométricos de éste; caracterizado porque comprende la desacetilacion selectiva de un compuesto de formula (5) en la que R1 es alquilo (C1-6), alquenilo (C2-6), alquinilo (C2-6), estando los grupos alquilo, alquenilo o alquinilo (C2-6) opcionalmente sustituidos con uno a tres halo, en presencia de una enzima hidrolítica y una solucion tampon acuosa. un procedimiento caracterizado porque la enzima hidrolítica es una lipasa.A process for the preparation of a compound of formula 1 in which A is selected from CH2 and NR; B, D and E are independently selected from CH and N; Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4; (b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4; (c) C3-8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4; (d) C3-8 cycloalkynyl, optionally substituted with 1-2 substituents independently selected from R4; (e) a five-membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S (O) n-, optionally substituted with 1-3 substituents independently selected from R4, (f) a six-membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S (O) n-, optionally substituted with 1-3 substituents independently selected from R4; or (g) a bicyclic ring system consisting of a five to six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR2-, NR2- and - S (O) n-, optionally substituted with 1-3 substituents independently selected from R4; Z1 is (a) - (CH2) pW (CH2) q-; (b) -O (CH2) pCR5R6-; (c) -O (CH2) pW (CH2) q; (d) -OCHR2CHR3-; or (e) -SCHR2CHR3-; G is (a) -NR7R8; (b) formula (2) in which n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S-, or -CH2-; optionally condensed on adjacent carbon atoms with one or two phenyl rings and optionally and independently substituted on carbon with one to three substituents and optionally and independently, on nitrogen with a chemically suitable substituent selected from R4; or (c) a bicyclic amine containing from five to twelve carbon atoms, which forms a bridge or is condensed, and optionally substituted with 1-3 substituents independently selected from R4; Combined Z1 and G may be formula (3); W is (a) -CH2-; (b) -CH = CH-; (c) -O-; (d) -O-; (d) -NR2-; (that N-; (f)> C = O, (g) -CR2 (OH) -; (h) -CONR2-; (i) -NR2CO-; (j) formula (4) or (k) ûCsC-; R is hydrogen or (C1-6) alkyl; R2 and R3 are independently (a) hydrogen; or (b) (C1-4) alkyl; R4 is (a) hydrogen; (b) halogen; (c) C1-6 alkyl; (d) (C1-4) alkoxy; (e) acyloxy (C1-4); (f) C 1-4 alkylthio; (g) (C1-4) alkylsulfinyl; (h) C 1-4 alkylsulfonyl; (i) hydroxyalkyl (C1-4); (j) aryl (C1-4) alkyl; (k) -CO2H; (l) -CN; (m) -CONHOR; (n) -SO2NHR; (o) -NH2; (p) C 1-4 alkyl amino; (q) dialkyl (C1-4) amino; (r) -NHSO2R; (s) -NO2; (t) -aryl; or (u) -OH: R5 and R6 are independently (C1-8) alkyl or together form a C3-10 carbocyclic ring; R7 and R8 are independently (a) phenyl; (b) a saturated or unsaturated carbocyclic (C3-10) ring (c) a heterocyclic (C3-10) ring containing up to two heteroatoms, selected from O-, -N- and -S-; (d) H, (e) C1-6 alkyl; or (f) form a 3 to 8 member ring containing nitrogen with R5 or R6; R7 and R8 in a linear or ring form may be optionally substituted with up to three substituents independently selected from (C1-6) alkyl, halogen, alkoxy, hydroxy, and carboxy; the ring formed by R7 and R8 may optionally be condensed with a phenyl ring; () e y () n are (CH2) and y (CH2) n respectively; e is 0, 1 or 2 ;; m is 1, 2 or 3; n is 0, 1 or 2; p is 0, 1, 2, or 3; q is 0, 1, 2 or 3; and its optical and geometric isomers; characterized in that it comprises the selective deacetylation of a compound of formula (5) in which R1 is (C1-6) alkyl, (C2-6) alkenyl, (C2-6) alkynyl, the alkyl, alkenyl or (C2 alkynyl) groups being -6) optionally substituted with one to three halo, in the presence of a hydrolytic enzyme and an aqueous buffer solution. a procedure characterized in that the hydrolytic enzyme is a lipase.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20241800P | 2000-05-08 | 2000-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031844A1 true AR031844A1 (en) | 2003-10-08 |
Family
ID=22749787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102123A AR031844A1 (en) | 2000-05-08 | 2001-05-04 | ENZYMATIC RESOLUTION OF SELECTIVE MODULATORS OF STROGEN RECEIVERS |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US6828134B2 (en) |
| EP (1) | EP1156120B1 (en) |
| JP (1) | JP2002000293A (en) |
| KR (1) | KR100488385B1 (en) |
| CN (1) | CN1322842A (en) |
| AR (1) | AR031844A1 (en) |
| AT (1) | ATE346159T1 (en) |
| AU (1) | AU782597B2 (en) |
| BR (1) | BR0101802A (en) |
| CA (1) | CA2346426C (en) |
| CZ (1) | CZ20011576A3 (en) |
| DE (1) | DE60124616T2 (en) |
| ES (1) | ES2274854T3 (en) |
| HK (1) | HK1040264A1 (en) |
| HU (1) | HUP0101874A3 (en) |
| ID (1) | ID30106A (en) |
| IL (2) | IL142881A (en) |
| MX (1) | MXPA01004626A (en) |
| PL (1) | PL347407A1 (en) |
| RU (1) | RU2213778C2 (en) |
| SG (1) | SG100688A1 (en) |
| TW (1) | TWI237059B (en) |
| YU (1) | YU31101A (en) |
| ZA (1) | ZA200103666B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| CN109750013B (en) * | 2019-03-27 | 2023-01-13 | 云南师范大学 | Lipase mutant and preparation method and application thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814282A (en) * | 1984-05-03 | 1989-03-21 | Abbott Laboratories | Centrifuge for two-dimensional centrifugation |
| DE3638762A1 (en) | 1986-11-13 | 1988-05-26 | Schering Ag | RACEMAT CLEAVAGE OF 7 (ALPHA) -ACYLOXY-6SS-HYDROXY-METHYL-2-OXABICYCLO (3.3.0) OCTAN-3-ONES BY STEREO-SPECIFIC ENZYMATIC ACYLATE HYDROLYSIS |
| US5248609A (en) * | 1986-11-13 | 1993-09-28 | Schering Aktiengesellschaft | Racemic separation of 7α-acyloxy-6β-hydroxymethyl-2-oxabicyclo[3.]-octan-3-ones by stereospecific enzymatic acylate hydrolysis |
| CA1319144C (en) * | 1986-11-14 | 1993-06-15 | Quirico Branca | Tetrahydronaphthalene derivatives |
| US5106750A (en) * | 1988-08-30 | 1992-04-21 | G. D. Searle & Co. | Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents |
| HU215441B (en) * | 1989-11-13 | 1999-04-28 | Pfizer Inc. | Process for the preparation of endo-bicyclo [2.2.1] -heptan-2-ol and the enzymatic separation of the resulting active ingredients |
| TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| GB9304256D0 (en) * | 1993-03-03 | 1993-04-21 | Chiros Ltd | Arylalkanoic acid resolution |
| FR2724184B1 (en) * | 1994-09-05 | 1997-01-03 | Rhone Poulenc Chimie | PROCESS FOR THE RESOLUTION OF A MIXTURE OF STEREOISOMERIC ALCOHOLS |
| US5589482A (en) * | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (en) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| EP1002123A1 (en) * | 1997-06-17 | 2000-05-24 | Schering Corporation | Enzymatic kinetic resolution of an intermediate useful for preparing substituted tricyclics |
| HN1999000097A (en) | 1998-06-16 | 1999-11-03 | Pfizer Prod Inc | COMBINATION THERAPY FOR MUSCOLOSKELETAL FRAGILITY |
| ATE265853T1 (en) * | 1998-06-16 | 2004-05-15 | Pfizer Prod Inc | COMBINATION THERAPEUTICS CONTAINING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND PROSTAGLANDIN E2 |
| ID23459A (en) | 1998-08-28 | 2000-04-27 | Pfizer Prod Inc | MICROBIAL BIOTRANSFORMATION |
| US6180375B1 (en) | 1999-08-27 | 2001-01-30 | Pfizer Inc. | Microbial biotransformation |
-
2001
- 2001-04-19 AT AT01303554T patent/ATE346159T1/en not_active IP Right Cessation
- 2001-04-19 ES ES01303554T patent/ES2274854T3/en not_active Expired - Lifetime
- 2001-04-19 EP EP01303554A patent/EP1156120B1/en not_active Expired - Lifetime
- 2001-04-19 DE DE60124616T patent/DE60124616T2/en not_active Expired - Fee Related
- 2001-04-26 YU YU31101A patent/YU31101A/en unknown
- 2001-04-26 CN CN01117132A patent/CN1322842A/en active Pending
- 2001-04-30 IL IL142881A patent/IL142881A/en not_active IP Right Cessation
- 2001-04-30 IL IL168341A patent/IL168341A/en not_active IP Right Cessation
- 2001-05-02 TW TW090110515A patent/TWI237059B/en not_active IP Right Cessation
- 2001-05-04 CZ CZ20011576A patent/CZ20011576A3/en unknown
- 2001-05-04 ID IDP00200100361D patent/ID30106A/en unknown
- 2001-05-04 AR ARP010102123A patent/AR031844A1/en unknown
- 2001-05-04 CA CA002346426A patent/CA2346426C/en not_active Expired - Fee Related
- 2001-05-07 JP JP2001136141A patent/JP2002000293A/en active Pending
- 2001-05-07 KR KR10-2001-0024679A patent/KR100488385B1/en not_active Expired - Fee Related
- 2001-05-07 HU HU0101874A patent/HUP0101874A3/en unknown
- 2001-05-07 AU AU43758/01A patent/AU782597B2/en not_active Ceased
- 2001-05-07 US US09/850,545 patent/US6828134B2/en not_active Expired - Fee Related
- 2001-05-07 ZA ZA200103666A patent/ZA200103666B/en unknown
- 2001-05-07 RU RU2001112671/13A patent/RU2213778C2/en not_active IP Right Cessation
- 2001-05-07 MX MXPA01004626A patent/MXPA01004626A/en active IP Right Grant
- 2001-05-07 PL PL01347407A patent/PL347407A1/en not_active Application Discontinuation
- 2001-05-08 SG SG200102673A patent/SG100688A1/en unknown
- 2001-05-08 BR BR0101802-7A patent/BR0101802A/en not_active IP Right Cessation
-
2002
- 2002-03-14 HK HK02101977.3A patent/HK1040264A1/en unknown
-
2004
- 2004-03-02 US US10/791,462 patent/US7351567B2/en not_active Expired - Fee Related
-
2007
- 2007-06-28 US US11/769,776 patent/US20070249025A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2721268T3 (en) | Pyrazolo [1,5-a] pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | |
| ES2170252T3 (en) | TETRAHYDROIMIDAZOPIRIDOINDOLDIONAS AS INHIBITORS OF SPECIFIC CGMP PDE. | |
| ES8507534A1 (en) | Phenoxyalkoxy-3,4-dihydro-2H-1-benzopyran derivatives. | |
| ES2172303T3 (en) | THERAPEUTIC AGENTS OBTAINED BY ENZYMATIC CATALYSIS. | |
| MX2019010408A (en) | FORMULATION OF ANTI-VRS MONOCLONAL ANTIBODY. | |
| PE20190339A1 (en) | 1H-PIRAZOLO [4,3-B] PYRIDINES AS INHIBITORS OF PDE1 | |
| MX9303441A (en) | PROCEDURE FOR THE PREPARATION OF CLAVULANIC ACID. | |
| AR058095A1 (en) | TRIAZOLOPIRIDINE DERIVATIVES IN QUALITY OF LIPASE AND PHOSPHOLIPASE INHIBITORS. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. | |
| CO5580788A2 (en) | BENCIMIDAZOL COMPOUNDS REPLACED USEFUL AS PROTEIN CINASE INHIBITORS | |
| PE20211703A1 (en) | NOVEL HETEROTHYCLICAL DERIVATIVE COMPOUND AND USE OF THE SAME | |
| AR051753A1 (en) | METHODS TO PREPARE INDAZOL COMPOUNDS | |
| FR2619111B1 (en) | (PIPERIDINYL-4) METHYL-2 TETRAHYDRO-1,2,3,4 9H-PYRIDO (3,4-B) INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
| PE20170949A1 (en) | SPIROINDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF INFECTION BY RESPIRATORY SYNCITIAL VIRUS (RSV) | |
| PE20171335A1 (en) | LYSINE GINGIPAINE INHIBITORS | |
| DK0903347T3 (en) | New Cyclodepsipeptide PF1022 Derivatives | |
| BR112012007179B8 (en) | dihydro-orotate dehydrogenase inhibitor compound, and pharmaceutical formulation | |
| DE60318826D1 (en) | ALKOXYPYRIDINDERIVATE | |
| DOP2010000136A (en) | WET GRANULATION USED BY A WATER SEQUENCING AGENT | |
| AR031844A1 (en) | ENZYMATIC RESOLUTION OF SELECTIVE MODULATORS OF STROGEN RECEIVERS | |
| PE20141527A1 (en) | DERIVATIVES OF 2-AMINO-3- (IMIDAZOL-2-IL) -PYRIDIN-4-ONA, PREPARATION OF THE SAME AND THEIR THERAPEUTIC USE OF THE SAME | |
| AR006261A1 (en) | BRADIQUININE HETERO-CYCLIC ANTAGONISTS, SUBSTITUTED WITH FLUOROALKYL FLUOROALCOXI, PROCEDURE FOR ITS PREPARATION AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND SAID MEDICINAL PRODUCT | |
| DE60121587D1 (en) | CYCLIC GMP SPECIFIC PHOSPHODIESTERASE INHIBITORS | |
| AR048717A1 (en) | DERIVATIVES OF HEXENOIC ACID, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR THERAPEUTIC APPLICATIONS | |
| ES2095848T3 (en) | NEW DERIVATIVES OF PHOSFOLIPIDS AND THEIR USE FOR THE PREPARATION OF ANTIVIRIC MEDICINES. | |
| PE20181895A1 (en) | CINNOLIN-4-AMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |